Genomic medicine is an approach to take advantage of genomic data in medical 
Implementation of genomic medicine has emerged in many developed countries. In the USA, several companies and institutions launched services and projects to use somatic mutation data in personalized cancer treatment. Application of genomic medicine in clinics has been supported by the US government, as the former president, President Obama, launched the precision medicine initiative in January 2015. In 2016, the French government decided to invest 670 million euro in promoting genomic medicine and personalized medicine. Genomics England started whole genome sequencing of 100 000 patients with rare diseases and their families, as well as patients with common cancers. Although Japan was a slow starter, the Japanese government decided to support the development of systems and infrastructures for personalized medicine in the field of rare undiagnosed diseases and cancer. It is obvious that collaboration is of paramount importance for the implementation of personalized medicine. Adequate knowledge and strategies of genomic medicine need to be shared not only by the researchers and informaticians in medical and genomic studies, but also by physicians and medical coworkers in clinics, and together they need to make efforts to benefit cancer patients in a cost-effective way ( Figure 1 ). 
| INCIDENTAL/SECONDARY FINDINGS IN NGS PANEL TESTS FOR SOMATIC MUTATIONS
As panel sequencing includes genes responsible for cancer susceptibility, it is possible to identify germline mutations in cancer tissues.
In the case of analysis of tumor tissue alone, the origin of mutations may be indistinguishable from germline variants, but other clinical 
| ASSESSMENT OF CANCER SUSCEPTIBILITY FOR EVIDENCE-BASED HEALTH CARE
Prevention and early detection are two of the most effective strategies to avoid death from malignant neoplasms. Family history is important information for the assessment but the determination of deleterious mutation in the responsible genes will give us more ben- 
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These pieces of information are useful to understand the mechanisms of resistance in refractory tumors, and may be applicable for selection of other drugs or modalities that are effective in secondary mutation. However, in many cases, resistance originates from multiple non-mutational, non-genetic mechanisms. 30 Therefore, incorporation of transcriptome, epigenome, proteome, and metabolome into genomic information is needed for precise assessment of resistant mechanism(s). Integration of these data together with information on drug efficacy, toxicity, and resistance will be a vital challenge for the promising development of specific and effective precision medicine. 
| CHALLENGES FOR BETTE R PRECISION ONCOLOGY
Although cost-effectiveness of genetic testing is an important matter of concern from the financial point of view, it will not be discussed here because it is beyond the scope of this review. Current challenges for medical oncology include the interpretation of variations in the individual genome and in the cancer genome. Larger collaborations and data repositories are needed for the assessment of less common variants, which otherwise might elude statistical analysis.
Accumulating genomic data are rapidly expanding and now overflowing beyond our recognition. In the near future, we will obtain epigenomic, proteomic, metabolomic, and microbiota information that will require clinical interpretation. Therefore, it is a matter of pressing necessity to develop integrative databases and analytical systems for 
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